Machine Learning for PK/PD Modeling in Drug Development Blog 医薬品開発におけるPK/PDモデリングのための機械学習 Pharmacometricians can use machine learning for PK/PD modeling to help them characterize the safety and…Certara2025年3月4日
Pharmacometrics Drug Development Decision Support: Model-Based Meta-Analysis (MBMA) Fact Sheet ファーマコメトリクスによる医薬品開発の意思決定支援:モデルに基づくメタ解析(MBMA) Danielle Pillsbury2025年2月19日
Certara’s Phoenix Platform – The world’s most trusted platform for PK/PD analysis and modeling Video サターラのPhoenixプラットフォーム ― PK/PD解析とモデリングにおける世界で最も信頼されるプラットフォーム 今日の医薬品候補は、これまで以上に複雑化しています。But with development decisions on the line,…Certara2025年2月12日
Simulations to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL6 Antibody, for Treatment of Thyroid Eye Disease Poster バセドウ病眼症の治療を目的とした完全ヒト型抗IL-6抗体TOUR006のフェーズ2b試験における用量選択を支援するためのシミュレーション Danielle Pillsbury2025年2月7日
Machine Learning for Population PK Model Selection: Theory and Practice On-Demand Webinar Machine Learning for Population PK Model Selection: Theory and Practice Three of Certara's expert modelers provide a gentle introduction to machine learning in our field.…Danielle Pillsbury2025年2月7日
Simcyp Version 24: Advancing PBPK capabilities and translating new science and technology into regulatory-accepted predictive modeling On-Demand Webinar Simcyp Version 24: Advancing PBPK capabilities and translating new science and technology into regulatory-accepted predictive modeling With the release of Version 24, the Simcyp Simulator introduces cutting-edge enhancements that further elevate…Danielle Pillsbury2025年2月7日
Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies Publication 再発または難治性の骨髄線維症およびその他の骨髄系・固形腫瘍を対象としたNavtemadlinの集団薬物動態・薬力学解析 This study conducted a population pharmacokinetic (PK) and pharmacodynamic (PD) analysis of navtemadlin, an MDM2…Danielle Pillsbury2025年2月6日
Understanding Variability in CAR-T Cell Therapy Kinetics Publication Understanding Variability in CAR-T Cell Therapy Kinetics Axicabtagene ciloleucel (axi-cel), a CAR-T cell therapy for relapsed and refractory non-Hodgkin’s lymphoma (NHL), demonstrates…Danielle Pillsbury2025年1月23日
Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA) On-Demand Webinar Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA) In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…Danielle Pillsbury2025年1月9日
Preclinical data exposures underpredict clinical physiologically active doses for bispecific T-cell engagers in solid tumors indications; are there better metrics? -insights from a small mechanistic MBMA Poster Preclinical data exposures underpredict clinical physiologically active doses for bispecific T-cell engagers in solid tumors indications; are there better metrics? -insights from a small mechanistic MBMA Danielle Pillsbury2024年12月11日